TABLE 2.
Baseline characteristics of the cohorts
| QFT− | QFT+ | TST+ | All subjects | |
| Total | 975 | 366 | 479 | 1820 |
| Total follow-up years | 2259.1 | 804.8 | 3308.3 | 6372.2 |
| Average follow-up years | 2.3 (1.8–2.7) | 2.2 (1.7–2.7) | 6.3 (5.9–6.9) | 2.5 (1.9–3.5) |
| Age at screening years | 25.2 (22.1–28.7) | 26.4 (22.8–29.5) | 24.3 (21.6–27.9) | 25.1 (22.1–28.6) |
| Female | 474 (48.6) | 146 (39.8) | 188 (39.2) | 808 (44.4) |
| World area of birth | ||||
| South Asia | 777 (79.7) | 303 (82.7) | 442 (92.2) | 1522 (83.6) |
| North Africa and Middle East | 39 (4.0) | 7 (1.9) | 19 (3.9) | 65 (3.6) |
| Sub-Saharan Africa | 58 (5.9) | 31 (8.4) | 9 (1.8) | 98 (5.4) |
| Eastern Europe and Russia | 53 (5.4) | 10 (2.7) | 0 (0) | 63 (3.5) |
| Western Europe | 0 (0) | 0 (0) | 4 (0.8) | 4 (0.2) |
| East and south-east Asia | 47 (4.8) | 12 (3.2) | 4 (0.8) | 63 (3.5) |
| South America | 1 (0.1) | 1 (0) | 0 (0) | 2 (0.1) |
| Unknown | 0 (0) | 2 (0.5) | 1 (0) | 3 (0.2) |
Data are presented as n, median (interquartile range) or n (%). QFT: QuantiFERON; TST: tuberculin skin test.